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Mitochondrial ADP/ATP carriers transport ADP into
the mitochondrial matrix for ATP synthesis, and
ATP out to fuel the cell, by cycling between cyto-
plasmic-open and matrix-open states. The structure
of the cytoplasmic-open state is known, but it has
proved difficult to understand the transport mecha-
nism in the absence of a structure in the matrix-
open state. Here, we describe the structure of the
matrix-open state locked by bongkrekic acid bound
in the ADP/ATP-binding site at the bottom of the
central cavity. The cytoplasmic side of the carrier is
closed by conserved hydrophobic residues, and a
salt bridge network, braced by tyrosines. Glycine
and small amino acid residues allow close-packing
of helices on the matrix side. Uniquely, the carrier
switches between states by rotation of its three
domains about a fulcrum provided by the sub-
strate-binding site. Because these features are
highly conserved, this mechanism is likely to apply
to the whole mitochondrial carrier family.
INTRODUCTION
Solute transport across the impermeable mitochondrial inner
membrane is essential for the function and survival of eukaryotic
cells. The majority of these transport steps are catalyzed by
membrane proteins of the mitochondrial carrier family (Monne´
and Palmieri, 2014). The archetypal member of the family, the
ADP/ATP carrier, performs the vital role of transporting ADP
into the mitochondrial matrix and ATP out of the mitochondrion
to maintain high cytosolic ATP concentrations for energy-
requiring reactions (Kunji et al., 2016). Every day, this carrier
transports our own body weight in ADP and ATP, recycling
each ATP molecule more than a thousand times. The carrier
cycles between the cytoplasmic-open state (c-state), which
can be trapped by the membrane-impermeable toxic inhibitor
carboxyatractyloside (CATR) (Vignais et al., 1973), and theCell 176, 1–13, J
This is an open access article undmatrix-open state (m-state), which is locked by the membrane-
permeable bongkrekic acid (BKA) (Erdelt et al., 1972; Henderson
and Lardy, 1970). BKA is a polyunsaturated methoxy tricarbox-
ylic acid polyketide produced by Burkholderia gladioli patholog-
ical variant cocovenenans (de Bruijn et al., 1973; van Veen
and Mertens, 1934). Over 2,000 cases of human fatality from
BKA poisoning have been reported in Indonesia, China, and
Mozambique since 1950, due to contamination of corn or coco-
nut products (tempe bongkrek) (Anwar et al., 2017; Falconer
et al., 2017).
Mitochondrial carriers consist of three homologous sequence
repeats of about 100 amino acids (Saraste and Walker, 1982),
which form a 3-fold pseudosymmetrical structure with the trans-
location path through the center of the molecule (Kunji and Har-
ding, 2003). The first atomic structure of the CATR-inhibited
bovine ADP/ATP carrier (Pebay-Peyroula et al., 2003) was fol-
lowed by those of yeast ADP/ATP carriers in the same state
(Ruprecht et al., 2014). Each sequence repeat forms a domain,
comprising an odd-numbered transmembrane helix (H1, H3, or
H5), a loop containing a short matrix helix lying parallel to the
membrane (h12, h34, or h56), and an even-numbered trans-
membrane helix (H2, H4, or H6) (Pebay-Peyroula et al., 2003).
In the C-terminal region of each odd-numbered transmembrane
helix, a conserved signature motif Px[DE]xx[KR] is found (Pebay-
Peyroula et al., 2003). The proline residues of this motif are
located at pronounced kinks in the odd-numbered helices,
giving them an L-shape. Consequently, these helices come
together on the matrix side, where the charged residues of the
three motifs form the matrix salt bridge network, closing the
central cavity to the mitochondrial matrix in the c-state (Pebay-
Peyroula et al., 2003).
Nucleotides are among the largest solutes to cross biological
membranes, yet mitochondrial carrier proteins are relatively
small. Transport must therefore involve profound conformational
changes, which nevertheless must prevent proton leak across
the mitochondrial inner membrane. Until now, the molecular
mechanism by which mitochondrial carriers transport has not
been established. However, some sequence features required
for a transport mechanism have been identified. First, a
consensus substrate-binding site has been proposed in the
central cavity (Dehez et al., 2008; Robinson and Kunji, 2006;anuary 24, 2019 ª 2018 The Author(s). Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Overall Structure of the Bongk-
rekic Acid-Inhibited ADP/ATP Carrier
(A) The structure of TtAac (rainbow cartoon) bound
to bongkrekic acid (ball-and-stick with orange
carbons) and a nanobody (Nb, wheat cartoon).
Cardiolipin molecules associated with the carrier
are shown as sticks (gray carbons) and a PEG
molecule is shown in ball-and-stick representation
(gray carbons).
(B) The carrier protein viewed from the membrane
(top), with domains 1, 2, and 3 colored in blue,
yellow, and red, respectively, and from the mito-
chondrial matrix side (bottom). Transmembrane
helices (H1 to H6) and matrix helices (h12, h34,
h56) are labeled.
(C) The BKA-inhibited carrier viewed from the
membrane with key functional elements high-
lighted. Residues of the substrate-binding site are
shown as sticks with green carbons. Positively
charged (blue carbons) and negatively charged
(red carbons) residues of the cytoplasmic and
matrix networks are also shown, along with their
braces (cyan carbons).
See also Figures S1–S5 and Table S1.
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https://doi.org/10.1016/j.cell.2018.11.025Robinson et al., 2008; Wang and Tajkhorshid, 2008). Second, a
conserved motif [YF][DE]xx[KR] was identified on the even-
numbered helices, the charged residues of which likely form a
cytoplasmic salt bridge network in the m-state (King et al.,
2016; Robinson et al., 2008; Ruprecht et al., 2014). It has been
proposed that substrate binding leads to the interconversion of
states by disruption and formation of the cytoplasmic andmatrix
salt bridge networks, opening and closing the carrier to either
side of the membrane (Kunji et al., 2016; Robinson and Kunji,
2006; Ruprecht et al., 2014). Here, we have determined the
structure of the ADP/ATP carrier inhibited by BKA, which repre-
sents the first structure of a carrier in an m-state conformation
and reveals the molecular mechanism of transport utilized by
mitochondrial carrier proteins.2 Cell 176, 1–13, January 24, 2019RESULTS
A Nanobody-Stabilized
BKA-Inhibited ADP/ATP Carrier
Structure
Mitochondrial carriers are highly dynamic
proteins, and the m-state is known to be
unstable in detergent solution (Crichton
et al., 2015), which has hampered struc-
ture determination. To solve these
problems, we targeted the BKA-inhibited
ADP/ATP carrier from the moderately
thermophilic fungus Thermothelomyces
thermophila (TtAac, Figure S1), carrying
a single mutation (Q302K) in the cyto-
plasmic network that increases the
thermal stability (King et al., 2016).
Furthermore, we selected a nanobody
against this state and crystallized the
complex (see STAR Methods for details).TtAac has 75% sequence identity to Saccharomyces cerevisiae
ScAac2 and ScAac3 and 51% sequence identity to bovine
Aac1p, the structures of which have been determined
in the CATR-inhibited state (Pebay-Peyroula et al., 2003;
Ruprecht et al., 2014). Crystals diffracted anisotropically to
3.3 A˚ (Table S1, TtAac-Nb crystal), enabling structure determina-
tion (Figure S1).
The crystal is composed of alternating layers of carrier and
nanobody molecules, with crystal contacts between the carrier
layers being mediated by the nanobodies (Figure S2). The carrier
consists of six transmembrane helices surrounding a central
cavity (Figure 1). The structural fold has the characteristic
three-domain structure of this protein family (Figure 1B). Thema-
trix salt-bridge network (E37, K40, D142, R145, D242, and R245)
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Figure 2. Alternating Access in the ADP/ATP Carrier
(A and B) Surface view of the BKA-inhibited carrier (A; m-state) and of the
CATR-inhibited S. cerevisiae Aac2p carrier (B; c-state, PDB: 4C9H). The blue
semi-transparent surfaces reveal the internal cavities. The residues of
the substrate-binding site (spheres with green carbons) lie at the center of
the membrane and are alternately accessible to the mitochondrial matrix
(BKA-inhibited carrier) or cytoplasmic (CATR-inhibited carrier) sides of the
membrane.
(C and D) The BKA-inhibited carrier (C) and CATR-inhibited carrier (D) viewed
from the mitochondrial matrix.
(E and F) The BKA-inhibited carrier (E) and the CATR-inhibited carrier (F)
viewed from the cytoplasmic side of the membrane. They are shown as a
surface colored by electrostatic potential (blue, +15 kT e1; white, neutral;
red, 15 kT e1).
The positions of the matrix helices are indicated in (C)–(E).
See also Figures S4 and S5.
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https://doi.org/10.1016/j.cell.2018.11.025and cytoplasmic salt-bridge network (D101, K104, D205, K208,
D299, and K302) flank the proposed central substrate-binding
site (K30, R88, G192, I193, Y196, S238, and R287) (Figure 1C).
The carrier binds one molecule of BKA and several cardiolipin
molecules, which bind to positively charged pockets due to the
N-terminal dipoles of the matrix and even-numbered transmem-
brane helices (Figure S3).
Comparison of the BKA-inhibited carrier structure with
the CATR-inhibited c-state structure of the homologousS. cerevisiae ADP/ATP carrier Aac2p (ScAac2, PDB: 4C9H) re-
veals a profound conformational change (Figure 2). The BKA-
inhibited m-state has a central cavity open to the mitochondrial
matrix side of the membrane, with the matrix helices rotated out-
ward (Figures 1 and 2). In the m-state, the cavity is closed to the
cytoplasmic side of the membrane by a cluster of residues that
includes those of the cytoplasmic salt bridge network (Figures
1C and S4). In the c-state, which is open to the cytoplasmic
side, the cytoplasmic network residues are far apart, whereas
the matrix salt bridge network residues are interacting, helping
to close the carrier on the matrix side (Pebay-Peyroula et al.,
2003; Ruprecht et al., 2014). Solvent accessibility calculations
map out the geometry of the central cavity in both states and
reveal that each state has an15 A˚ thick gate, closing off access
to the central cavity from one side of themembrane and thus pre-
venting proton leak (Figures 2A and 2B). The consensus residues
of the proposed substrate-binding site (Kunji et al., 2016), which
we confirm are essential for the function of TtAac (Figure S5), are
accessible for substrate binding in both states. This observation
provides structural support for the single-binding center gated
pore hypothesis (Klingenberg, 1979), which is essentially an
alternating access model (Jardetzky, 1966). Comparing surface
representations shows the dramatically different shapes of the
two states (Figures 2C–2F). Viewed from the matrix side, the
m-state has a strong positively charged central cavity around
the substrate-binding site, primed for binding negatively charged
ATP (Figure 2C), whereas access to the cavity is closed in the
c-state with a predominantly neutral surface (Figure 2D). Viewed
from the intermembrane space, the cavity is closed in the
m-state, with a predominantly neutral surface, except for a small
positively charged patch (Figure 2E), whereas a positively
charged cavity is visible in the c-state (Figure 2F).
A Gate Blocks Access from the Cytoplasmic Side
The structure reveals that in the m-state, the charged residues of
the cytoplasmic salt bridge network, part of the conserved [YF]
[DE]xx[KR] motif (Figure S4), come into close proximity and
form electrostatic interactions, linking the even-numbered trans-
membrane helices of each domain (Figure 3A) in agreement with
functional data (King et al., 2016). K104 on H2 forms a salt bridge
with D205 on H4, and K208 on H4 interacts with D299 on H6.
K302 on H6, which was mutated to stabilize the m-state (King
et al., 2016), interacts weakly with D101 on H2. In the wild-type
carrier, the corresponding residue is Q302, which whenmodeled
in silico is too far away to interact with D101 directly (Figure 3A,
inset). Close to the salt bridge residues, a highly conserved set of
tyrosine residues, positioned a turn of helix away from the posi-
tively charged residues of the network, unexpectedly act as
braces for the salt bridges, providing extra inter-domain interac-
tions (Figures 3A and S4). Y204 forms a hydrogen bond with
D299, bracing the K208-D299 salt bridge. Y298 forms a
hydrogen bond with D101, compensating for the weak D101-
K302 interaction. We call these extra interactions tyrosine
braces. ADP/ATP carriers are unusual in the mitochondrial car-
rier family in having a positively charged residue substituting
for tyrosine on H2 (Figure S4). Here, R100 forms electrostatic in-
teractions with both D101 (intra-domain) and D205, bracing the
K104/D205 salt bridge in an equivalent way to the tyrosineCell 176, 1–13, January 24, 2019 3
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Figure 3. Cytoplasmic Salt Bridge Network
and Gate
(A) Cytoplasmic salt bridge network and tyrosine
braces in the BKA-inhibited carrier, showing polar
interactions (black dotted lines) with indicated
distances (A˚). The inset shows interactions in the
wild-type carrier.
(B) View of the cytoplasmic salt bridge network
and brace in CATR-inhibited carrier (ScAac2,
PDB: 4C9H).
(A) and (B) are viewed from the cytoplasmic side of
the membrane.
(C) Mutation of R100 and Y204 residues bracing
the cytoplasmic network reduces the thermal
stability of BKA-inhibited carriers. The apparent
melting temperature is represented by the mean ±
SD, with n = 6 for mutants and n = 12 for wild-type.
(D) Schematic diagram illustrating the cytoplasmic
(c) and matrix (m) networks in TtAac. The circles
represent transmembrane helices, with numbers
indicating the corresponding helices. Polar inter-
domain interactions are marked by black dashes.
(E) The residual transport rates of brace mutants,
represented by the mean ± SD, with n = 4.
(F) The cytoplasmic gate in the BKA-inhibited
carrier.
(G) Cytoplasmic gate in theCATR-inhibited carrier.
(F) and (G) are viewed from the cytoplasmic side
of the membrane.
For (C) and (E), p > 0.05, not-significant (NS);
*p > 0.01, ***p > 0.0001, and ****p > 0.00001 by
two-tailed Student’s t test.
See also Figure S4 and Table S2.
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https://doi.org/10.1016/j.cell.2018.11.025braces. These tyrosine braces, which are part of the highly
conserved [YF][DE]xx[KR] motif, serve a similar function to the
glutamine braces observed for the matrix salt bridge network
(Ruprecht et al., 2014). The number of these braces vary in
different members of the mitochondrial carrier family, modu-
lating the interaction energy of the networks (Figure S4). Com-
parison with the c-state shows that the residues have moved
12–17 A˚ for the formation of the cytoplasmic network (Figure 3B).
We have previously studied the effect of cytoplasmic salt
bridge network mutations on the thermal stability of the BKA-in-
hibited carrier, showing that these interactions contribute signif-
icantly to the overall thermal stability of the protein in the matrix
state (King et al., 2016). The structure reveals that there are few
inter-domain interactions other than those of the cytoplasmic
salt-bridge network and brace residues, which is an important
functional feature of this highly dynamic protein. Therefore, the
relative network strength correlates well with the overall stability
of the protein. Here, we extend our analysis to include the tyro-
sine brace interactions (Figure 3C). In the BKA-inhibited state,4 Cell 176, 1–13, January 24, 2019mutation of R100 and Y204 significantly
reduces the thermal stability compared
to the wild-type protein, consistent with
these residues forming a brace that stabi-
lizes the m-state. Y298F did not have a
significant effect on thermal stability of
the BKA-inhibited state compared to thewild-type, consistent with the Y298-D101 bond forming the
weakest link in the network.
Previously, the effect of substrate-binding and salt bridge for-
mation and disruption on the transport rate was analyzed by
treating the carrier as a nanomachine moving stochastically be-
tween the m-state and c-state under the influence of thermal en-
ergy (Springett et al., 2017). This computational analysis shows
that maximum transport occurs when the interaction energies
of the cytoplasmic network, matrix network, and substrate bind-
ing are approximately equal. As a consequence, the analysis
predicted that interactions in addition to the cytoplasmic salt
bridge network should stabilize the matrix state. The current
structure reveals that the tyrosine braces provide these addi-
tional interactions, resulting in the cytoplasmic and matrix net-
works having similar numbers of polar interactions (Figure 3D).
The effect of mutations of the cytoplasmic salt bridge network
and braces on the transport rate was investigated (Figure 3E).
Mutations of residues involved in electrostatic interactions
(R100, K104, and K208) had the greatest effect on the transport
Please cite this article in press as: Ruprecht et al., The Molecular Mechanism of Transport by the Mitochondrial ADP/ATP Carrier, Cell (2019),
https://doi.org/10.1016/j.cell.2018.11.025rate, followed by Y204. Mutations of Q302 and Y298 had
only a mild effect. Thus, mutations of the strongest links in the
cytoplasmic network have the largest effects upon transport
and thermal stability, as expected from the structure of
the cytoplasmic network in the m-state and the computa-
tional model.
Just beneath the tyrosine brace residues, there are other aro-
matic or bulky hydrophobic residues (F97, F201, and L295) that
come together to form a hydrophobic plug. These residues
converge when the carrier is in the m-state (Figure 3F) but are
separate in the c-state (Figure 3G). The residues of the hydro-
phobic plug, together with the cytoplasmic salt bridge network
and tyrosine braces, form the cytoplasmic gate, which is highly
conserved in all members of the mitochondrial carrier family,
highlighting their important role in the transport cycle (Figure S4).
Another set of residues, which are variable within the mitochon-
drial carrier family, form the ceiling of the substrate-binding site
(N96, Y200, and V294).
Bongkrekic Acid Is a Conformation-Specific
Competitive Inhibitor
Electron density maps calculated following molecular replace-
ment revealed extra density in the cavity, not accounted for by
protein atoms. As model building and refinement progressed,
this density could be modeled as the inhibitor BKA (Figures 1,
4, S1C, and S6A).
BKA inhibits the carrier by binding deeply and asymmetrically
within the central cavity (Figures 1 and 4). The polyunsaturated
backbone of the inhibitor forms a horseshoe shape, allowing
the carboxylate groups at either end of the inhibitor to interact
with key amino acids that lie close together in space. BKA inter-
acts directly with all residues of the putative substrate-binding
site (Kunji et al., 2016), forming electrostatic interactions with
K30 and R88 and a hydrogen bond to Y196 (Figures 4B
and 4C). The carboxymethyl and distal carboxylate group at
either end of the inhibitor both form electrostatic interactions
with R197, and additional hydrogen bonds are formed to N96
and Y89. The large number of interactions formed between the
inhibitor and protein explains the tight binding of BKA (Fig-
ure S6B) (Klingenberg et al., 1983). ATP can be docked into
the binding site (Figure S6C), with the phosphate groups inter-
acting with K30, R88, and R287, and the adenine ring sitting in
a hydrophobic pocket formed by G192, I193, Y196, and S238
and potentially forming aromatic stacking interactions with the
tyrosine, in agreement with previous work based on the c-state
(Kunji et al., 2016). Comparison of the ATP and BKA binding ge-
ometries shows that the dicarboxylate end of BKA mimics the
phosphate groups of ATP, while the polyunsaturated backbone
of the inhibitor acts as a partial mimic of the adenine ring of
the substrate, sitting in the hydrophobic pocket (Figures S6C
and S6D). The position and steric bulk of the polyunsaturated
backbone would prevent the substrate from binding to the m-
state. BKA thus shows the characteristics of a conformation-
specific competitive inhibitor.
Random mutagenesis of the related ScAac2 has produced
mutant strains of yeast that are resistant to BKA but can still
growonnon-fermentable carbon sources, which requires the car-
rier to be functional (Zeman et al., 2003). Four mutations wereidentified and three of them are within the observed BKA-binding
site (Y97C, L142S, andG298S, equivalent to Y89, L135, andG291
in TtAac). These residues are in van der Waals contact with BKA
(Figure 4D), and the Y97C mutation would remove a hydrogen
bond to BKA. The fourth mutation lies within the GxxxG motif,
described below (Cappello et al., 2007). Interestingly, the key res-
idues involved in substrate-binding are not affected by thesemu-
tations, explaining why transport could still occur. The agreement
between the position of mutations and the BKA-binding site con-
firms that the observedBKAbindingpose reflects the one found in
ScAac2 in the native membrane. In another approach, the role of
residuesnear thecavity inbindingBKAhadbeenassessedprior to
structure determination by comparing the thermostability of the
BKA-inhibitedwild-typewith those of BKA-inhibitedmutants (Fig-
ure S6E). Mutating key residues involved in BKA-binding (e.g.,
K30, R88, N96, I193, Y196, and R197) reduced the stabilizing ef-
fect of BKA binding observed in the wild-type protein, consistent
with weaker binding of the inhibitor. Mutagenesis of R287 or
S238,which formweakvanderWaals interactionswithBKA rather
than polar interactions, did not significantly reduce the thermal
stability of the inhibitedcarrier. The thermal stability of themutants
in the presence of CATR confirms that they are folded correctly
(Figure S6F). Mutation of residues that are known to interact
with CATR in the closely related ScAac2 (Ruprecht et al., 2014),
has a strongeffect on thermal stability of theCATR-inhibited state,
whereas a weaker effect is seen for those that are further away,
confirming that thermostability assays can be used to map inhib-
itor-binding sites.
GxxxG and pxxxpMotifs Allow Close Packing of Helices
on the Cytoplasmic Side
In the BKA-inhibited state, transmembrane helices are packed
closely on the cytoplasmic side of the membrane, helping to
form the cytoplasmic gate. This is facilitated by amino acids
with small side chains lying at the intra-domain interfaces, which
include residues of the highly conserved GxxxG motif on the
odd-numbered helices (Figures 5 and S4) (e.g., G127 and
G131 on H3). Other conserved small residues are found on the
adjacent even-numbered helices (e.g., G198 and G202 on H4),
which we call the pxxxp motif after the one letter code for small
amino acids (Figures 5B and S4). A similar arrangement is seen in
domains 1 and 3 (Figures 5A and 5C). The requirement for
residues with small side chains at these positions explains their
conservation, which was not apparent from the c-state struc-
tures (Figures 5D and 5E).
For the inter-domain interfaces, close-packing of helices at the
cytoplasmic side is facilitated by conserved small amino acids
on the odd-numbered transmembrane helices, for example
A130 on H3 of domain 2. Residues on the even-numbered heli-
ces do not point directly at the interface but face the lipid bilayer
(L95 or F99) or cavity (N96, R100), hence larger side-chains can
be tolerated here. A similar arrangement is observed in all three
inter-domain interfaces in the m-state structure and also in the
c-state structures (Ruprecht et al., 2014).
Conformational Changes between C- and M-States
Comparison of the structures of the three domains in BKA- and
CATR-inhibited carriers (Figures 6A–6C) reveals that 80% ofCell 176, 1–13, January 24, 2019 5
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Figure 4. Structural Basis for Inhibition of the ADP/ATP Carrier by Bongkrekic Acid
(A) Structure of the inhibitor bongkrekic acid (BKA) with the stereochemistry of chiral centers and double bonds labeled.
(B) Overview of the inhibitor-binding site. The carrier is shown as a wheat cartoon, with BKA in ball-and-stick representation (orange carbon atoms). Amino acid
residues forming the binding-pocket are shown in stick representation. Amino acids that are part of the putative substrate-binding pocket are shown with green
carbon atoms. Additional amino acids that form salt bridges or hydrogen bonds, or van der Waals interactions, are shown with blue or gray carbon atoms,
respectively.
(C) Detailed view of the BKA-binding site, with salt bridges shown as green dashed lines and hydrogen bonds as black dashed lines. Y89, which forms a hydrogen
bond to BKA, has been removed to provide a clearer view.
(D) Mutations that confer resistance to BKA (Zeman et al., 2003) affect residues that interact or are in van derWaals contact with BKA (yellow), but do not affect the
putative substrate-binding site (green). The contact points of the substrate-binding site are indicated by black spheres with white Roman numerals. The hydrogen
bond between Y89 and BKA is indicated by the black dashed line. The spheres indicate the van der Waals radii of the affected residues and BKA.
See also Figures S4 and S6.
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https://doi.org/10.1016/j.cell.2018.11.025the domain structure is conserved between the two states, which
we call the core element, comprising the odd-numbered, matrix,
linker, and one-third of the even-numbered helices. In particular,
there are no major changes to the kink angle around the proline
residues of the signature motif, consistent with the notion that
the kink is stabilized by interactions within the domain (Ruprecht
et al., 2014). The proposal that the conformational change may
involve these proline residues acting as hinges during transport,
with the odd-numbered helices straightening during the transi-6 Cell 176, 1–13, January 24, 2019tion to them-state (Pebay-Peyroula et al., 2003), is not supported
by the current structure. There is, however, a significant and un-
expected movement of the C-terminal region of the even-
numbered helices in all three domains toward the central axis
from the c- to them-state. Thus, the domains do notmove as sin-
gle rigid bodies and are more dynamic than originally anticipated
(Ruprecht et al., 2014). In them-state, theeven-numberedhelices
kink at R88 (H2), G192 (H4), and R287 (H6), which are key amino
acids predicted to be involved in substrate-binding, called the
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Figure 5. Role of Conserved Glycines and Residues with Small Side Chains
(A) Role of conserved small amino acids in the intra-domain interface. Domain 1 is highlighted (blue cartoon).
(B and C) Equivalent views for (B) domain 2 (yellow) and (C) domain 3 (red). Residues of the GxxxG motif and the pxxxpmotif are shown as magenta and green
spheres, respectively.
(D) Overview of residues forming the m-state intra-domain inter-helical interface, viewed from the cytoplasmic side of the membrane.
(E) Equivalent residues, shown in the c-state (PDB: 4C9H).
In (D) and (E), the carrier is shown in cartoon representation, with domains colored (domain 1, blue; domain 2, yellow; domain 3, red). Residues are shown as
spheres, colored as in (A)–(C).
See also Figure S4.
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https://doi.org/10.1016/j.cell.2018.11.025contact points of the substrate-binding site (Kunji and Robinson,
2006; Robinson and Kunji, 2006). The inward movement of these
helical regions (comprising the even-numbered helices from the
contact point to the C-terminal end), which we call the gate ele-
ments, contributes to bringing the residues of the cytoplasmic
network together. Conformational change from the c- to m-state
must involve rigid-body rotationsof thecore elements to open the
central cavity to themitochondrial matrix and inwardmovements
of the gate elements, closing the central cavity to the intermem-
brane space.
Inhibitor Binding Is Accompanied by Induced Fit
It has been proposed that the inhibitors CATR and BKA induce
structural perturbations of the c- and m-states, because the in-
hibitors have larger molecular volumes than the substrates andmaximize their interactions with the protein, thus increasing their
binding affinity (Klingenberg, 2008). The inhibited states have
therefore been called abortive states, which are not transport
cycle intermediates. Comparing the structures binding either
inhibitor allows us to investigate the structural consequences
of inhibition.
We initially analyzed the domain structures. For the CATR-in-
hibited carriers, while most of the domain structure is conserved,
there are noticeable deviations in the positions of the C-terminal
end of H2 and N-terminal end of H3 (Figure 6D). The structures of
the individual domains in the BKA-inhibited state superposewell,
indicating that the inhibitor has not perturbed the structures of
the domains themselves (Figure 6E).
To understand the consequences of CATR binding further, we
have taken the core and gate elements from the BKA-inhibitedCell 176, 1–13, January 24, 2019 7
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Figure 6. Conformational Changes between M- and C-States and
the Structural Consequences of Inhibitor Binding
(A) Structure of domain 1 in the m-state (blue cartoon) versus the c-state (PDB:
4C9H, outline).
(B and C) Similar views of (B) domain 2 (m-state yellow cartoon, c-state outline)
and (C) domain 3 (m-state red cartoon, c-state outline), respectively. The or-
ange spheres mark the positions of the conserved prolines of the signature
sequence Px[DE]xx[KR]. The numbered black spheres mark the positions of
the substrate-binding site contact points (Robinson and Kunji, 2006). Domains
have been aligned on their core elements.
(D) Superposition of domains 1 to 3 of CATR-inhibited ScAac2 (PDB: 4C9H,
colored by domain, as in A–C). The kink at the cytoplasmic-end of H2 is
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https://doi.org/10.1016/j.cell.2018.11.025structure and superposed them on the CATR-inhibited structure
(Figure 6F). Core elements 1 and 3 (from domains 1 and 3) align
very well, with root-mean-square deviations (RMSDs) of 0.97
and 1.16 A˚ for backbone atoms, respectively (Figures 6A and
6C). However, core element 2 does not align well, with an
RMSD of 2.25 A˚ for backbone atoms (Figure 6B). Fitting core
element 2 with outlier rejection revealed that while most of the
structure fits well, there is a deviation at the N-terminal end of
H3, due to change in the kink angle at the Pro of the signature
motif (from 76 in the CATR-inhibited state to 43.0 in the BKA-
inhibited state). When aligning the gate elements, H4 and H6
aligned well (backbone RMSDs of 0.95 and 0.85 A˚, respectively),
but H2 did not (backbone RMSD of 1.76 A˚). Closer inspection
found that this misalignment is due to the helix of the BKA-
inhibited structure being straight, whereas that of the CATR-
inhibited structure is kinked at Phe107 in CATR-inhibited ScAac2
(Phe99 in TtAac). This kink is caused by Lys108 interacting with
the two sulfate groups of CATR, pulling H2 down and bringing
the C-terminal end close to the end of H3, which is consequently
displaced as well (Figure 6G). The deviations in the positions of
H2 and H3 observed here are consistent with those seen when
comparing the CATR-inhibited domains alone (Figure 6D).
Therefore, the action of CATR is 2-fold—first, it acts as a
competitive inhibitor by binding to the substrate-binding site,
and second, it induces a structural change in H2 and H3 that
locks the carrier in an abortive state.
A noticeable difference between the BKA- and CATR-inhibited
states is that the CATR-inhibited state is highly symmetrical, in
agreement with the presence of three homologous sequence
repeats, whereas the BKA-inhibited state is 3-fold pseudosym-
metric at the cytoplasmic side but somewhat asymmetrical at
the matrix side. To investigate the cause, we symmetrized the
BKA-inhibited structure, while treating the domains as rigid
bodies (Figure 6H), in agreement with our analysis of the domain
structures (Figure 6E). Comparing the two structures, the posi-
tions of domains 2 and 3 are similar, but domain 1 is displaced
toward the matrix side. In agreement, the cardiolipin-bindingindicated by a blue triangle and is also highlighted in (A). The yellow triangle
highlights the displacement of H3, also apparent in (B).
(E) Superposition of domains 1 to 3 of BKA-inhibited TtAac (colored by domain,
as in A–C), confirming the conservation of domain structure.
(F) Superposition of gate and core elements from the BKA-inhibited structure
(colored by domain, as in A–C) and CATR-inhibited structure (PDB: 4C9H,
colored gray).
(G) CATR binding induces a bend of H2 because K108 on H2 of ScAac2
(equivalent to R100 in TtAac) interacts electrostatically with the two sulfate
groups of CATR. Displacement of the cytoplasmic end of H2 induces a similar
displacement of H3.
(H) Superposition of the crystal structure of BKA-inhibited TtAac (gray cartoon)
and the uninhibited m-state model (colored by domain as in A–C). The unin-
hibited m-state model was generated by applying symmetry restraints be-
tween the domains, while treating them as rigid bodies. BKA induces a
displacement of the matrix side of domain 1. The cytoplasmic side of the
carrier is unaffected.
(I) Comparison of BKA-inhibited and uninhibited m-state models suggests that
the domain 1 displacement is due to the steric bulk of the inhibitor, combined
with electrostatic repulsion between one of the BKA carboxyl groups and E37
on H1. Domain 3 has been removed to provide a clearer view of the inhibitor.
See also Figures S3, S4, and S7.
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structure, with good electron density present for the lipid (cdl
802), but the sites between domains 1 and 3 and domains 1
and 2 are disrupted (Figures 1 and S3). To exclude the unlikely
possibility that the domain displacement is a consequence of
crystal packing interactions or the nanobody interacting with
H1 (Figure S2), we solved the structure of the BKA-inhibited car-
rier from a crystal grown without the nanobody, which diffracted
anisotropically to 3.6 A˚ resolution (Table S1, TtAac crystal).
Although the crystal diffracts to lower resolution than the
TtAac-Nb crystal, it confirms that the structure of BKA-inhibited
TtAac is not significantly affected by nanobody binding (Fig-
ure S7). The displacement of domain 1 is therefore likely to be
due to inhibitor binding, leading to an abortive m-state. Closer
inspection shows two likely molecular reasons for the abortive
state. First, E37 in the symmetrized carrier lies in close proximity
to negatively charged groups of BKA, so electrostatic repulsion
may drive domain displacement. Second, the molecular volume
of the inhibitor (443 A˚3) is substantially greater than ATP (354 A˚3),
hence steric repulsion may also play a role (Figure 6I).
This comparison shows that the inhibitors perturb the struc-
ture of the protein, in agreement with earlier proposals. Both in-
hibitors occupy the positions where the substrates bind by
mimicking the biophysical properties rather than the exact
chemistry of the substrates and by forming multiple interactions
that prevent the substrate competing for binding. Carboxylate
groups of the inhibitors mimic the phosphate groups of the nat-
ural substrates. Furthermore, the binding itself distorts the struc-
ture of this highly dynamic protein, locking it in an abortive state
that cannot undergo the required conformational changes for
transport.
DISCUSSION
The available structures have revealed the conformational
changes undergone by the domains. Further insight requires
considering these domain changes in the context of the whole
protein. A morph between the CATR- and BKA-inhibited states
does not provide a plausible mechanism, because of the
absence of an occluded state and because of clefts appearing
in the lipid-facing part of the carrier. Having gained insight into
the nature of inhibitor-induced distortions, we can use models
of the uninhibited proteins to propose a plausible transport
mechanism. Because CATR and BKA bind to different states
of the protein, we generated a model of the uninhibited c-state
from the superposition of the core and gate elements of the
BKA-inhibited structure with the CATR-inhibited structure (Fig-
ure 6F). The uninhibitedm-statemodel is the symmetrizedmodel
from the BKA-inhibited structure (Figure 6H). This seems a more
reasonable approach than modeling the uninhibited m-state
from elements of the CATR-inhibited structure, due to the
CATR-induced kink in H2 and displacement of H3.
Superposition of the uninhibited c- and m-states allows us to
propose how the domainmotions affect the overall conformation
of the carrier, leading to opening and closing of the substrate-
binding site to either side of the membrane. The core elements
have a rocking motion of 15, which is essential for opening
and closing of the matrix side of the carrier (Figure 7A). Thegate elements rotate toward or away from the central pseudo-
symmetry axis, respectively closing or opening access to the
substrate-binding site from the intermembrane space (Fig-
ure 7A), with the contact points of the binding site acting as
pivots (Kunji and Robinson, 2006; Robinson and Kunji, 2006).
The conformational changes are small around the substrate-
binding site but become progressively larger toward either side
of the membrane (Figure 7B), indicating that the substrate-bind-
ing site acts as a fulcrum. Because the same substrate-binding
site is accessible from both c- and m-states, and ADP and
ATP are chemically related, the same process can apply in either
direction across the membrane, explaining the known equimolar
exchange activity. Atoms move predominantly parallel to the
membrane, with no significant movement perpendicular, consis-
tent with the transmembrane helices moving within the plane of
the lipid bilayer. We speculate that engagement of the contact
point residues with the substrate, leading to tighter interactions,
drives the inward movement of the gate elements and formation
of the cytoplasmic network. Concurrently, the cytoplasmic sides
of the core elements also move inward, causing the core ele-
ments to rock and to open the matrix side. The involvement of
all three contact points in substrate-binding makes it likely that
the movements of the core and gate elements are symmetrical
and simultaneous in all three domains, which also prevents
clashes or gaps appearing in the protein structure. These move-
ments lead to a coupled closing of the cytoplasmic side and an
opening of the matrix side in the transition from c- to m-states,
consistent with an alternating-access transport mechanism
(Figures 7C–7G). The fungal ADP/ATP carriers have an extra
turn of a-helix on the matrix end of H1, which is a loop in the
bovine carrier. This extra turn slides out of the translocation
pathway when the carrier transitions from the c- to the m-state,
allowing sufficient access to the binding site (Figure 7G).
The cavity leading to the substrate binding site in the uninhib-
ited m-state model is narrower than that of the c-state model
(Figures 7C, 7F, and 7G). Access of substrate to the m-state
binding site is likely to be facilitated by thermal energy driving ro-
tamer changes, changing the size of the entry. However, the size
difference between the cavities in the two statesmight reflect the
biophysical requirements for transport of negatively charged
nucleotides in the presence of a membrane potential. Import of
ADP, which has three negative charges, is opposed by themem-
brane potential. Therefore, the carrier has a large water-filled
cavity in the c-state to shield the substrate from the influence
of themembrane potential until it is bound to residues of the sub-
strate binding site. The negatively charged phosphate groups
are neutralized by interactions with the three positively charged
residues of the binding site (Kunji and Robinson, 2006), facili-
tating ADP import. The export of ATP, which has four negative
charges, is stimulated by the membrane potential, which is
maximal when shielding by water is minimal, explaining the rela-
tively small cavity in the matrix state. Once ATP is bound to the
central substrate binding site, a net negative charge remains,
which helps to drive export.
A morph between the uninhibited c- and m-states (Video S1)
demonstrates these proposals and passes through an occluded
state, in which the substrate-binding site is inaccessible from
either side of the membrane, which is essential for maintenanceCell 176, 1–13, January 24, 2019 9
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Figure 7. Proposed Transport Mechanism of the Mitochondrial ADP/ATP Carrier
(A) Conformational changes between models of the uninhibited c- and m-states viewed laterally from the membrane, with helices shown as cylinders. The three-
fold pseudosymmetry axis is shown as a dotted gray line. Conformational changes between c- and m-states can be described as a rotation of the core elements,
coupled with an inward movement of the gate elements. Core elements 1, 2, and 3 are colored by domain in blue, yellow, and red, respectively, and the gate
elements are colored gray. The asterisk marks the extra turn of a-helix on the matrix end of H1, seen in fungal ADP/ATP carriers.
(B) Conformational changes between c- and m-states use the substrate-binding site as a fulcrum. Alignment of models of the uninhibited c- (blue) and m-states
(red), with lines connecting equivalent Ca positions, generated by RAPIDO (Mosca and Schneider, 2008). Substrate-binding site residues are shown in green ball-
and-sticks. The 3-fold pseudosymmetry axis is shown as a dotted gray line.
(C–F) Models of the uninhibited c-state and m-states viewed from the cytoplasmic side of the inner mitochondrial membrane, (C) and (D) respectively, and from
the mitochondrial matrix, (E) and (F) respectively, colored and labeled as in (A). Loop regions between H2-H3 and H4-H5 have been omitted to provide a clearer
view of the core and gate elements.
(G) Accessibility of the substrate-binding site in the uninhibited carrier models. The carrier is shown as a cartoon colored as in (A). The blue semi-transparent
surface shows the internal cavities. ATP and ADP are shown in sphere representation in different views.
See also Video S1.
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https://doi.org/10.1016/j.cell.2018.11.025of the proton motive force across the inner mitochondrial mem-
brane. The structure of the BKA-inhibited carrier provides the
first insight into the structure of the m-state. It shows that the
ADP/ATP carrier functions as a monomer (Bamber et al., 2007;
Kunji and Crichton, 2010; Kunji and Harding, 2003), because
the conformational changes alter the overall molecular shape10 Cell 176, 1–13, January 24, 2019profoundly, precluding stable interactions between carriers.
The carrier has a single substrate-binding site that is alternately
accessible from either side of the membrane, in agreement with
inhibitor (Klingenberg, 1979) and sequence analysis (Robinson
et al., 2008). The structure demonstrates the formation of the
cytoplasmic salt bridge network in the m-state, showing that
Please cite this article in press as: Ruprecht et al., The Molecular Mechanism of Transport by the Mitochondrial ADP/ATP Carrier, Cell (2019),
https://doi.org/10.1016/j.cell.2018.11.025formation and disruption of the cytoplasmic and matrix salt
bridge networks are key features of the transport cycle (King
et al., 2016; Robinson et al., 2008; Ruprecht et al., 2014). It has
also explained all of the conserved sequence features of mito-
chondrial carriers, including the role of bulky hydrophobic resi-
dues in forming the cytoplasmic gate and the role of the GxxxG
and pxxxpmotifs in the dynamic conformational changes of the
inter-helical interfaces during the transport cycle. Because these
sequence features are conserved, it is likely that the proposed
mechanism holds for all mitochondrial carriers, which constitute
the largest solute carrier family in humans. The mechanism is
unique among transport proteins, as it involves coupled rotations
of three domains, with each domain undergoing two separate ro-
tations, leading to alternating access from opposite sides of the
membrane to the substrate-binding site. Together with the
CATR-inhibited structures, this structure provides a framework
for further biophysical and structural analysis of the intermediary
states of the transport cycle, which will elucidate how substrates
drive the conformational changes and how pathological muta-
tions affect transport activity.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Wild-type ADP/ATP carriers for biophysical and structural studies were expressed in Saccharomyces cerevisiae strain WB-12 (MATa
ade2-1 trp1-1 ura3-1 can1-100 aac1::LEU2 aac2::HIS3), and grown in YEPG at 30C. Mutant ADP/ATP carriers for biophysical
studies were expressed in Saccharomyces cerevisiae strain W303-1B (MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-
11,15), and grown in YEPG + 0.1% glucose at 30C. For transport assays, wild-type and mutant proteins were expressed in
Lactococcus lactis, using the expression vector pNZ8048 and a nisin A-inducible promoter, and grown in M17 media supplemented
with 1% (w/v) glucose and 5 mg/ml chloramphenicol. Nanobodies were expressed in E. coli strainWK6 (su-), grown in Terrific Broth at
28C to an OD600 of 0.7-1.2 and induced with 1 mM isopropyl-b-D-thiogalactoside.
The project involved the generation of camelid antibodies for which llamas need to be immunized and blood samples collected.
This is all done in compliance with both the European legislation (EU directive 2010/63/EC) and the Belgian Royal Decree of 29
May 2013 concerning the protection of laboratory animals with the exception that the animals are not specifically bred for such
use. There are no breeders yet that do this. The llamas are housed in a center (farm) which is licensed by the Belgian competent au-
thorities (accreditation number LA 1700601) and all staff involved is appropriately trained. The animals are very well taken care of and
have plentiful access to food, drink and movement. The welfare of the llamas is being supervised by an accredited veterinarian. The
immunization and blood collection of the llamas has been approved by the authorized local Animal Ethics Review board. The
approval reference number is 13-601-3 and is valid until 30/09/2021.
METHOD DETAILS
Thermostability analysis of wild-type and mutant ADP/ATP carriers
Wild-type and mutant ADP/ATP carriers were expressed and purified using established procedures (King et al., 2016). The gene for
the ADP/ATP carrier from Thermothelomyces thermophila (TtAac), encoding residues 8-311, was engineered with an upstream
N-terminal His8 tag and Factor Xa protease cleavage site, and ligated into a modified pYES3 vector. Mutants of TtAac for biophysical
characterization were produced by overlap-extension PCR. Expression vectors were electroporated into Saccharomyces cerevisiae
strain W303-1B. Positive transformants were selected on Sc-Trp plates. Cells containing the desired construct were grown in 5 L of
YEPG + 0.1% glucose at 30C for 24 h, or in 50 L of YPGmedium in an Applikon 140 Pilot Systemwith an eZ controller. Mitochondria
were prepared and proteins purified as described in King et al. (2016), but with 2% dodecyl-b-D-maltoside (Glycon BiochemicalsCell 176, 1–13.e1–e5, January 24, 2019 e2
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(7-diethylamino-4-methyl-3-coumarinyl)phenyl] maleimide (CPM) (Alexandrov et al., 2008), as described previously (King
et al., 2016).
Transport assays of wild-type and mutant ADP/ATP carriers
For transport assays, wild-type andmutant proteins were expressed in Lactococcus lactis, using the expression vector pNZ8048 and
a nisin A-inducible promoter. Following expression, membranes were isolated and fused with liposomes, and transport rates deter-
mined by measuring uptake of 14C-labeled ADP. Full details of these methods have been described previously (King et al., 2016).
Expression and purification of BKA-inhibited ADP/ATP carriers
The construct for the thermostabilized (Q302K mutation) ADP/ATP carrier from Thermothelomyces thermophila (TtAac), encoding
residues 8-311, engineered with an upstream N-terminal His8 tag and Factor Xa protease cleavage site, was produced in a modified
pYES3 vector as described previously (King et al., 2016). For purification of carrier-nanobody complexes, a modified construct was
produced by PCR, encoding a Q302K mutation and MetSer upstream of residues 4-315 of the carrier, but without the His8 tag and
Factor Xa site. The expression vectors were transformed by electroporation into Saccharomyces cerevisiae strain WB-12 (MATa
ade2-1 trp1-1 ura3-1 can1-100 aac1::LEU2 aac2::HIS3) (Hashimoto et al., 1999). Transformants were selected initially on Sc-Trp
plates, and then on YEPG plates. For large scale fermentations, a 2-L pre-culture was used to inoculate 100 L of YEPG medium
in an Applikon 140 Pilot System with an eZ controller. Cells were grown at 30C for 72 h and harvested by centrifugation (4,000g,
20 min, 4C). Mitochondria were prepared by disrupting cells with a bead mill (Dyno-Mill Multilab, Willy A. Bachofen AG Maschinen-
fabrik, Switzerland), as described (Thangaratnarajah et al., 2014). The total mitochondrial protein concentration was adjusted to
20 mg/mL with 0.1M MES pH 6.5, 10% glycerol. Mitochondria were flash frozen in liquid nitrogen, and stored at 80C before use.
BKA-inhibited His-tagged TtAac was purified starting from 1 g of mitochondria. Carriers were inhibited with 2 nmol bongkrekic acid
(BKA, Sigma Aldrich) per mg mitochondrial protein, supplemented with 250 mM ADP (50 mL final volume), and two Roche Complete
Mini EDTA-free protease inhibitor tablets at room temperature for 30 min. Subsequent steps were performed at 4C. Mitochondria
were pelleted by centrifugation (48,000g, 15 min, 4C), the supernatants removed, and the pellets resuspended in an equal volume of
100mMTris pH 7.4, 10%glycerol. Mitochondria were solubilized in 2%decyl maltose neopentyl glycol (10-MNG, Anatrace) solution,
with 20mM imidazole, 150mMNaCl, 5 mMBKA and two Roche Complete Mini EDTA-free protease inhibitor tablets, in a final volume
of 90 mL, for 1 h at 4C. The solubilizate was clarified by centrifugation (200,000g, 30 min, 4C) before loading onto a 1-mL Ni Se-
pharose column (GE Healthcare, High Performance). The column was washed with 40 mL of buffer A (10 mM Tris pH 7.4,
150 mM NaCl, 20 mM imidazole, 0.1 mg/mL tetraoleoyl cardiolipin (Avanti Polar Lipid), 0.02% 10-MNG, 5 mM BKA), followed by
25 mL of buffer B (10 mM Tris pH 7.4, 50 mM NaCl, 0.05 mg/mL tetraoleoyl cardiolipin, 0.02% 10-MNG, 10 mM BKA), at a flow
rate of 3 mL/min. The Ni Sepharose was recovered as a slurry (total volumez2 mL), supplemented with 10 mM CaCl2 and 60 mg
Factor Xa protease (NEB), and incubated overnight at 10C. The slurry was transferred into empty Proteus 1-Step Batch Mini
Spin columns (Generon) and the protein was eluted from the resin by centrifugation (500g, 5 min, 4C). Residual Ni Sepharose
was removed by an additional centrifugation step (12,000g, 10min, 4C). The protein concentration was determined by BCA (Thermo
Scientific), using bovine serum albumin as standard. Protein for crystallization experiments was concentrated to 2.5 mg/mL using
centrifugal concentrators (Amicon Ultra 50 K).
Purification of nanobody targeting BKA-inhibited carrier
For nanobody generation, one llama (Lama glama) was immunized with BKA-inhibited thermostabilized TtAac, which had been re-
constituted into 1,2-dioleoyl-sn-glycero-3-phosphocholine:tetraoleoyl cardiolipin (20:1 g/g ratio, Avanti Polar Lipid) liposomes at a
10:1 lipid:protein ratio (wt:wt), using established methods (Lee et al., 2015). A phage display library of nanobodies was prepared
in the pMESy4 vector from peripheral blood lymphocytes as described (Pardon et al., 2014). Nanobodies were identified by selecting
phages that bound to solid-phase immobilized proteoliposomes in the presence of BKA, and confirming lack of binding to CATR-
inhibited protein reconstituted into proteoliposomes, or to empty liposomes. Six nanobody families were identified that specifically
bound the BKA-inhibited protein, one of which included the nanobody used for crystallization and structure determination (nanobody
CA9848). For purification of nanobody-carrier complexes, nanobody constructs were modified by introducing a Factor Xa cleavable
C-terminal His8 tag via PCR. Nanobodies were expressed in the periplasm of E. coli strain WK6 (su-), following methods described
previously (Pardon et al., 2014). Briefly, 1-L cultures in Terrific Broth were grown to an OD600 of 0.7-1.2 and induced with 1 mM
isopropyl-b-D-thiogalactoside. Cells were harvested after overnight growth at 28C, and periplasmic extract prepared using TES
(Tris EDTA Sucrose) buffer. Nanobodies were purified from the periplasmic extract by Ni-NTA (QIAGEN) affinity chromatography.
Purification of BKA-inhibited TtAac-Nb complexes
Mitochondria (500-650 mg total protein) were inhibited with 2 nmol bongkrekic acid (BKA, Sigma Aldrich) per mg mitochondrial pro-
tein, supplementedwith 20 mMADP (final volume of 25mL), at room temperature for 2 h. All subsequent stepswere performed at 4C.
Mitochondria were pelleted by centrifugation (48,000g, 15 min, 4C), the supernatants were removed, and the pellets were resus-
pended in an equal volume of Tris-buffered saline. Mitochondria were solubilized in 2% 10-MNG (Anatrace) solution, with 20 mM
imidazole, 150 mM NaCl, 5 mM BKA and one Roche Complete Mini EDTA-free protease inhibitor tablet, in a final volume ofe3 Cell 176, 1–13.e1–e5, January 24, 2019
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added to the solubilizate and incubated for 30 min at 4C, before adding Ni Sepharose (GE Healthcare, High Performance, 0.5 mL
resin) and continuing the incubation overnight. The suspension was poured into an empty XK16 column (GE Healthcare) and packed
by gravity flow. The column was washed with 15.5 mL of buffer C (10 mM Tris pH 7.4, 150 mM NaCl, 20 mM imidazole, 0.02 mg/mL
tetraoleoyl cardiolipin (Avanti Polar Lipid), 0.35% HEGA-10 (Anatrace), 5 mMBKA), followed by 17 mL of buffer D (10 mM Tris pH 7.4,
150 mMNaCl, 10 mM imidazole, 10 mMCaCl2, 0.35%HEGA-10, 10 mMBKA), at a flow rate of 0.4 mL/min. The slurry was recovered
(volumez1.3 mL), supplemented with 30 mg Factor Xa protease and incubated at 10C for 2 h. The slurry was transferred into empty
Proteus 1-Step Batch Mini Spin columns (Generon) and protein was eluted from the resin by centrifugation (500g, 5 min, 4C). The
protein was concentrated to a 0.5 mL volume using centrifugal concentrators (Amicon Ultra 50 K) and applied to a 4-mL Sephadex
G75 column (GE Healthcare) packed in an empty PD10 column (GE Healthcare) and equilibrated with 10 mM Tris pH 7.4, 50 mM
NaCl, 0.35%HEGA-10, 10 mMBKA. The protein was applied and eluted by gravity flow, with the TtAac-Nb complex eluting in volume
fractions between 0.5-1.5 mL. The protein was concentrated to A280z8-10 using centrifugal concentrators (Amicon Ultra 50 K) and
used in crystallization trials.
Crystallization
Crystals were grown using the sitting drop vapor diffusion technique. Crystallization plates were set up with drop ratios of 200 nL
protein and 200 nL precipitating solution, or 500 nL of protein and 500 nL of precipitating solution, using a Mosquito robot (TTP
Labtech). Crystals of TtAac were grown at 22C using a precipitating solution of 90 mM HEPES pH 7.0, 1.8% 3-methyl-3-pentanol,
30% PEG600 and 0.5 mM dodecyl-b-D-maltoside (Glycon Biochemicals GmbH). Crystals were harvested from the drops and flash
frozen in liquid nitrogen. Crystals used for structure determination of the TtAac-Nb complex came from two conditions setup at 4C,
either: 0.1M HEPES pH 7.5, 3% 3-methyl-3-pentanol, 18% PEG400; or 0.1M MES pH 6.5, 1% 3-methyl-3-pentanol, 22% PEG400.
Crystallization plates were incubated at 10C, and crystals appeared within 3 days. Crystals were cryo-protected using PFO (Sigma
Aldrich) or LV (Mitegen) cryo oils, and flash frozen in liquid nitrogen.
Data collection and structure determination
Diffraction data for the TtAac crystal were collected at 100 K at the European Synchrotron Radiation Facility beamline ID23-2 with a
Mar 225 CCD detector using a 10 mmmicrofocus X-ray beam (0.8729 A˚ wavelength). Diffraction data for the TtAac-Nb crystals were
collected at 100 K at Diamond Light Source beamline I24 with a Pilatus 6M detector using a 9x6 mmmicrofocus X-ray beam (0.9686 A˚
wavelength). Datawere collected using helical data collectionmethods. Datasets were indexed, integrated, scaled andmerged using
the programs XDS (Kabsch, 2010) and AIMLESS (Evans andMurshudov, 2013), as implemented in AutoPROC (Vonrhein et al., 2011).
Due to the anisotropic diffraction from the crystals, datasets were ellipitically truncated and corrected using STARANISO (Tickle et al.,
2018), as implemented in AutoPROC. Data collection statistics are shown in Table S1.
Structure determination of the TtAac-Nb complex was initiated using a crystal that diffracted anisotropically to 3.9 A˚ along
0.894 a* - 0.447 b*, 3.9 A˚ along b* and 3.1 A˚ along c*. Analysis by phenix.xtriage (Adams et al., 2010) showed that the crystal was
untwinned. Phases were determined by molecular replacement in PHASER (McCoy et al., 2007), by searching sequentially with a
homology model of the Nb (based on PDB: 5IMK; translation function Z score (TFZ) = 8.1, log likelihood gain (LLG) = 43), then
with a homology model for domain 1 (residues 16-45 and 61-90 based on CATR-inhibited Saccharomyces cerevisiae ScAac2,
PDB: 4C9H chain A; TFZ = 10.8, LLG = 113). Domain 2 (residues 116-152 and 165-208 based on PDB: 4C9H chain A) could be placed
by molecular replacement, but it was clear from the electron density maps, and from maps produced after density modification with
Parrot (Cowtan, 2010), that the C-terminal end of H4 was in a different position. This region was rebuilt, and molecular replacement
with domain 2 repeated (TFZ = 16.6, LLG = 297). At this stage, electron density maps allowed themanual placement and rebuilding of
domain 3 (residues 226-252 and 262-294). Density features, such as the extra turn of helix on thematrix side of H1, as observed in the
yeast c-state structures (Ruprecht et al., 2014), helped to confirm the arrangement of domains. Iterative cycles of model building in
Coot (Emsley et al., 2010) and refinement in Buster (Bricogne et al., 2017) were carried out. B-factor sharpened maps were used to
help confirm side-chain positions. Refinement with Buster used LSSR restraints and grouped B-factors (2 per residue, for main chain
and side chain). In the early stages of model building and refinement, LSSR restraints were from the nanobody homology model, and
a carrier homology model based upon PDB: 4C9H chain A. In later stages, LSSR restraints were based on models of the TtAac-Nb
complex that had been refined with phenix.refine (Afonine et al., 2012) using secondary structure restraints. B-factor refinement
included TLS parameterization (1 TLS group per chain). Diffraction data were collected from a crystal diffracting to higher resolution
(statistics in Table S1), also untwinned, and model building and refinement were continued using these data, maintaining the flagged
reflections from the earlier dataset for calculating Rfree. BKA was modeled into positivemFo-DFc difference electron density present
in the central cavity. Several factors were considered during the modeling of BKA: (1) the stereochemistry of the ligand, combined
with minimal geometrical distortions following refinement, (2) minimal clashes with protein residues, (3) maximal number of pro-
tein-ligand interactions, (4) maximal cross-correlation with the 2mFo-DFc density map. Refinement statistics are shown in
Table S1. The final model consists of residues 11-252 and 257-306 of TtAac, residues 1 to 124 of the nanobody, a molecule of
BKA and of PEG, and partially modeled cardiolipins in the asymmetric unit. The cardiolipin between domains 2 and 3 has good den-
sity. However, density for cardiolipins between domains 1 and 2 and domains 1 and 3 is of poorer quality, due to the BKA-induced
displacement of domain 1 making it impossible for cardiolipins to bridge the distance between the even-numbered transmembraneCell 176, 1–13.e1–e5, January 24, 2019 e4
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https://doi.org/10.1016/j.cell.2018.11.025and matrix helices. Both these cardiolipins have been modeled as partial lipids at both positions. It is likely that these cardiolipins
interact predominantly with either the even-numbered transmembrane or matrix helix, stochastically throughout the crystal.
Residues M250-S252 and K257 of the carrier lie in very weak electron density in this crystal, but their position is supported by
good density in the earlier crystal.
Phases for the TtAac structure (without nanobody) were determined by molecular replacement with PHASER (McCoy et al., 2007),
searching with carrier domains from the TtAac-Nb model (domain 1: residues 13-107, domain 2: residues 116-211, and domain 3:
220-306; TFZ = 17.2, LLG= 378). Rigid-body refinementwas carried out in Buster (Bricogne et al., 2017), with each domain defined as
a rigid-body, reaching R = 36.2%, Rfree = 37.1%. The resulting electron density maps showed density for features not included in the
model (loop regions, BKA and cardiolipin phosphates, Figure S7). The carrier structure superposes very well with that solved from the
TtAac-Nb crystals (RMSD of 0.6 A˚ over 1096 matched atoms). Splitting domain 1 into smaller rigid sub-domains, or performing jelly-
body refinement in REFMAC, did not change the structure.
Comparisons of the TtAac BKA-inhibitedm-state structure with the ScAac2CATR-inhibited c-state shown in the figures used PDB:
4C9H chain A. The program HOLLOW (http://hollow.sourceforge.net) was used to generate the blue semi-transparent surfaces
shown in Figures 2A, 2B, and 7G. Protein structure figures were generated in PyMOL. The polder OMIT map (Liebschner et al.,
2017) for BKA was calculated after perturbing the TtAac-Nb model by removing the BKA coordinates and subjecting the model to
coordinate and group B-factor refinement in phenix.refine. The coordinates of BKAwere added back prior to polder map calculation,
to define the region for bulk solvent exclusion while being excluded from map calculation.
Models of the uninhibited c- and m-states
The model of the uninhibited c-state of TtAac was generated by superposing the core and gate elements from the BKA-inhibited
TtAac structure onto the structure of CATR-inhibited ScAac2p (PDB: 4C9H chain A) in PyMOL. Superposition of the backbones
of core domains 1 and 3, and of even-numbered helices 4 and 6 could be accomplished without outlier rejection. Superposition
of the backbones of core domain 2 and even-numbered helix 2 required outlier rejection and refinement, as implemented in the align
command. As discussed in the manuscript, these differences are attributable to CATR-induced protein distortions. The superposed
elements of the TtAac crystal structure provided an initial model for the uninhibited c-state, which was completed by loop building
based upon the available crystal structures. The structure was energy-minimized in Chimera (Pettersen et al., 2004), rotamer outliers
were corrected in PyMOL, and the geometry was checked by Molprobity (Chen et al., 2010).
To create a model of the uninhibited m-state of TtAac, the structure of the BKA-inhibited carrier was initially symmetrized using
Modeler 9.19 (Sali and Blundell, 1993), applying a symmetry restraint with weight 2 between the Ca atoms of domains 1 and 2
and between the Ca atoms of the respective symmetry-related residues of domains 2 and 3. Symmetrization corrected the displace-
ment of domain 1, resulting in domain 1/domain 2 and domain 1/domain 3 interfaces with suitable geometry for cardiolipin-binding.
The symmetrised models were used as a template for placing the domains from the crystal structure, treating the domains as rigid
bodies. This provided an initial model for the uninhibited m-state, which was completed by loop building based upon the available
crystal structures. The geometry was checked by Molprobity (Chen et al., 2010), rotamer outliers were corrected in PyMOL, and the
structure was energy-minimized in UCSF Chimera (Pettersen et al., 2004) to reduce clashes.
The models of the uninhibited states were aligned using RAPIDO (Mosca and Schneider, 2008), prior to generating a morph in
Chimera (Pettersen et al., 2004).
QUANTIFICATION AND STATISTICAL ANALYSES
For CPM-based thermostability analysis, the apparent melting temperature was calculated from the first derivative of the thermal
denaturation profile, and represented by the average and standard deviation of three technical repeats (Figures S6E and S6F)
or six repeats (n = 3 with two biological repeats, for Figure 3C). Significance was assessed by a two-tailed Student’s t test assuming
equal variance, with P values indicated as follows: p > 0.05, not-significant (NS); p > 0.01, *; p > 0.001, **; p > 0.0001,
***; p > 0.00001, ****. The null hypothesis is that themutation has no effect upon themelting temperature of the BKA-inhibited protein.
For the transport studies, the residual transport rate is represented by the average and standard deviation of four technical
repeats, with each mutant having its own wild-type comparison (Figures 3E and S5A). Significance was assessed by a two-tailed
Student’s t test assuming unequal variance, with P values indicated as follows: p > 0.05, not-significant (NS); p > 0.01,
*; p > 0.001, **; p > 0.0001, ***; p > 0.00001, ****. The null hypothesis is that the mutation has no effect upon the transport rate.
DATA AND SOFTWARE AVAILABILITY
Coordinates, structure factor amplitudes and Fourier map coefficients for the nanobody-bound BKA-inhibited mitochondrial ADP/
ATP carrier (TtAac-Nb) have been deposited in the Protein Data Bank under accession number PDB: 6GCI. The structure factor
file includes structure factors for the P212121 TtAac crystal as a second data block. CPM and transport assay data have been depos-
ited as a Mendeley dataset (https://doi.org/10.17632/x4xdfh6gt2.1).e5 Cell 176, 1–13.e1–e5, January 24, 2019
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Figure S1. Alignment of the Amino Acid Sequences of Selected Mitochondrial ADP/ATP Carriers and Representative Electron Density of the
TtAac-Nb Complex, Related to Figure 1
(A) Alignment of the mitochondrial ADP/ATP carriers from Thermothelomyces thermophila (TtAac), from Saccharomyces cerevisiae isoform 2 (ScAac2) and
isoform 3 (ScAac3), and bovine (BtAAC1) and human (HsAAC1) isoform 1. Amino acids are colored according to their properties: basic K, R and H are blue, acidic
D and E are red, polar N, Q, S and T are green, aliphatic A, I, L, M and V are pink, aromatic F, Y andW are orange, structural G and P are magenta, and C is yellow.
The negatively charged (red) and positively charged (blue) residues of the matrix and cytoplasmic networks are indicated by up and down triangles, respectively.
The positions of the glutamine brace (Q brace) and tyrosine brace (Y brace) are indicated by green and cyan squares, even if they are not conserved in ADP/ATP
carriers. The purple and lime circles indicate the positions of the GxxxG and pxxxp motifs. The contact points of the substrate binding site are shown in black
circles with roman numerals (Robinson and Kunji, 2006). (B) Stereo-view showing the contents of the asymmetric unit, with the carrier shown in rainbow colored
ribbon representation, and the nanobody as a wheat ribbon. A PEG molecule is shown in ball-and-stick representation, and partially-modeled cardiolipins as
sticks. The blue mesh shows the final 2mFo-DFc electron density map, contoured at 1 times the root mean square electron density, and shown within 5 A˚ of the
atoms. (C) Detailed view of the bongkrekic acid-binding site. BKA is shown with orange carbons. Amino acids that are part of the putative substrate-binding
pocket are shown with green carbon atoms. Additional amino acids that form salt bridges or hydrogen bonds, or van der Waals interactions, are shown with blue
or gray carbon atoms, respectively. The blue mesh shows the final 2mFo-DFc electron density map, sharpened by applying a negative B-factor (B = 45 A˚2),
contoured at 1 times the root mean square electron density, and shown within 5 A˚ of the atoms. (D) Detailed view of the cytoplasmic salt bridge network and
brace. The blue mesh shows a different view of the map in (C).
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Figure S2. Interactions between Nanobody and ADP/ATP Carrier, Related to Figure 1
(A) Crystal packing shows alternating layers of carrier proteins (Aac, gray cartoon, with one molecule highlighted as a rainbow cartoon) and nanobodies (Nb,
wheat cartoon), with the nanobodies playing key roles in forming crystal contacts. (B) In the crystal, each ADP/ATP carrier molecule (Aac, gray cartoon) interacts
with one nanobody (wheat cartoon, interactions highlighted in black box) via the nanobody CDR2 (blue) and CDR3 (red) loops, and with a symmetry-related
nanobody (violet cartoon, interactions highlighted in blue box). (C) An enlarged view of the interactions involving the nanobody CDR2 and 3 loops. The CDR3 loop
interacts with the matrix end of H1, the matrix helix h12, and the loop connecting them, via hydrogen bond and electrostatic interactions (between D56 of the
carrier and R99 of the nanobody). (D) An enlarged view of the interactions with a symmetry-related nanobody (violet cartoon), with A155 and R161 of the carrier
forming hydrogen bonds with Q119. These interactions are likely to be solely due to crystal packing.
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Figure S3. Bound Cardiolipin Acts as an Inter-domain Bridge, Related to Figures 1 and 6
(A) Cardiolipin binding sites (ball-and-stick representation, with gray carbon atoms) with cdl802 highlighted. The protein is shown in surface representation,
colored by electrostatic potential (blue, +10 kT e-1; white, neutral; red, 10 kT e-1). Cardiolipin phosphates occupy pockets with positive electrostatic potential.
(B) Detailed view of the binding site for cdl802. Cardiolipin phosphate groups form hydrogen bonds with the amide groups at the N-terminal ends of the even-
numbered and matrix helices, and interact with the positively-charged ends of the helix dipoles, as seen in the c-state (Ruprecht et al., 2014). The cardiolipin
molecule is shown in ball-and-sticks. Amino acids making interactions with the lipid are shown as thin sticks. Residues in the conserved [YWF][RK]G and [YF]xG
motifs are shown in purple and green, respectively. Hydrogen bond and electrostatic interactions between protein and lipid are shown by cyan dashed lines. The
helix dipoles associated with the even-numbered and matrix helices are shown (blue, d+, to red, d-), and intra-helical hydrogen bonds are shown as thin dashed
black lines.
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Figure S4. Alignment of Symmetry-Related Triplets from Yeast and Human Carrier Sequences, Related to Figures 1, 2, 3, 5, and 6
(A) The odd-numbered helices and (B) even-numbered helices of different mitochondrial carriers of Saccharomyces cerevisiae (Sc), Homo sapiens (Hs),
Musculus musculus (Mm), and Aspergillus oryzae (Ao). The residues are shown as a triplet of symmetry-related residues of domain 1, 2 and 3 together to
emphasize the symmetry in the three-fold repeats of mitochondrial carriers (Robinson et al., 2008). Below the triplets are the corresponding numbers of the
residues in TtAac that form the symmetry-related triplet. Amino acids are colored according to their properties as in Figure S1. Indicated above are the functional
elements of mitochondrial carriers and the contact points of the substrate binding site in black circles with roman numerals (Robinson and Kunji, 2006). Fig-
ure adapted from Figures S1 and S3 from Robinson et al. (2008). Copyright (2008) National Academy of Sciences.
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Figure S5. Transport Activity and Growth on Glycerol of Alanine Replacement Mutants of the Substrate-Binding Site Residues of TtAac,
Related to Figures 1, 2, and 4
(A) Transport assays in fused membrane vesicles of Lactococcus lactis, expressing the wild-type and single alanine replacement mutants of TtAac. (B) Drop test
on YPG plates of yeast expressing wild-type and single alanine replacement mutants of TtAac, showing that none of the binding site mutants are capable of
growing on glycerol. R100A serves as a control.
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Figure S6. Binding of Bongkrekic Acid and ATP, Related to Figure 4
(A)mFo-DFc polder OMIT electron density map for BKA, contoured at 3 times the root mean square electron density, shown with the final model. Q93 and Y200,
which are in hydrophobic contact with BKA, have been removed to provide a clearer view. (B) Schematic drawing of the binding-site, showing amino acid
residues within 4 A˚ of BKA. Hydrogen bonds and salt bridges are shown as green dashed lines with indicated distances (A˚). Red arcs indicate residues in hy-
drophobic contact with the inhibitor, with spokes radiating toward the atoms they contact. Figure generated by Ligplot+ (Laskowski and Swindells, 2011).
(C) Putative binding mode of ATP. The model was generated by docking in AutoDock 4.2 (Forli et al., 2016), treating the protein as a rigid molecule and with S238
modeled as an alternative common rotamer. The model shows the adenine ring of ATP binding to a hydrophobic pocket formed by residues Y196 (aromatic
stacking), G192 and I193. S238 may form a hydrogen bond to the adenine ring, and R197 a hydrogen bond to the ribose (black dotted lines). The phosphate
groups of ATP interact with the positively-charged residues K30, R88 and R287 (green dotted lines). The features of this binding site mimic those predicted for
ADP binding to the c-state (Dehez et al., 2008; Kunji and Robinson, 2006; Mifsud et al., 2013; Robinson and Kunji, 2006; Wang and Tajkhorshid, 2008). (D) View of
the BKA binding-site from the matrix side, highlighting residues in the putative substrate-binding site (shown in stick representation). Electrostatic interactions
between these residues and BKA are shown as dotted green lines, and hydrogen bonds as dotted black lines. The view is the same as (C) illustrating the overlap
between the BKA and ATP-binding site. (E) Mutation of binding-site residues reduces the thermal stability of BKA-inhibited variants. Residues forming polar
interactions with BKA, or proximal to the inhibitor, are highlighted in red. (F) Binding-site mutants show increased thermal stability in the presence of CATR, hence
are folded correctly and able to bind the inhibitor. CATR induces a greater stabilization than BKA. Mutation of residues that form salt bridges to CATR (R88, R197),
or form the binding-pocket (G192, I193, Y196, S238) (Ruprecht et al., 2014), reduces the apparent melting temperature of the CATR-inhibited protein. These
residues are shown with red bars. Mutation of residues distal to CATR (K30, S238) results in a smaller reduction in apparent melting temperature. In (E) and (F),
the apparent melting temperature is represented by the mean ± S.D., with n = 3. p > 0.05, not-significant (NS); p > 0.01, *; p > 0.0001, ***; p > 0.00001, **** by
two-tailed Student’s t test.
Figure S7. Comparison of BKA-Inhibited M-State Structures from Crystals Grown with and without Nanobody, Related to Figure 6
(A) Superposition of m-state carrier structures from crystals grown with nanobody (P3221 space group, gray tube) and without nanobody (P212121 space group,
tube with domain 1, blue; domain 2, yellow; domain 3, red), viewed from themembrane. The structures superimpose with 0.6 A˚ RMSD over 1096 atoms, showing
that presence of the nanobody, different detergent and crystallization conditions, and different crystal packings have not perturbed the structure of the BKA-
inhibited state. (B) The same superposition as (A), viewed from the cytoplasmic side of the membrane. (C) Stereo-view of electron density maps for the P212121
crystal form, following molecular replacement (using individual domains from the P3221 crystal) and rigid-body refinement in AutoBuster. The P3221 structure is
shown as a gray cartoon, with the P212121 colored by domain. (D) Electron density for domain 1. (E) Partial density for BKA, not included in the molecular
replacement search models, gives confidence in the quality of the molecular replacement phases. In (C)-(E), the 2mFo-DFc electron density map, contoured
at 1 times the root mean square electron density (s), is shown as a blue mesh, and themFo-DFc electron density map is shown contoured at +3s (green mesh)
and 3s (red mesh).
